IZEA Extends Profitability Momentum in Q3 2025 with $8.1 Million in Revenue

(NASDAQ:IZEA), $8.8 Million Year-Over-Year Improvement in Net ResultsPositive Cash from Operations ORLANDO, Fla., Nov. 12, 2025 (GLOBE NEWSWIRE) — IZEA Worldwide, Inc. (NASDAQ: IZEA), a leading influencer marketing company that makes Creator Economy solutions for marketers, reported its financial and operational results for the third quarter ended September 30, 2025. Q3 2025 Financial Summary Compared […]

Interlink Electronics Reports Third Quarter 2025 Results

(NASDAQ:LINK), Revenue Up 11% Year-over-Year, Marking Second Consecutive Quarter of Double-Digit GrowthBuilding Momentum for 2026 Through Continued Organic Growth and Strengthened M&A Pipeline FREMONT, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Interlink Electronics, Inc. (Nasdaq: LINK) (“Interlink” or the “Company”), a global leader in sensor technology and printed electronic solutions, today reported results for the

Usio Announces Third Quarter 2025 Financial Results

(NasdaqGM:USIO), Revenue up over $1 million sequentially from Second Quarter 2025 Total payment dollars processed through all payment channels up 8% versus the prior year period Sequential increase across all processing metrics for all divisions All-time quarterly records for all ACH processing metrics, Credit Card volume, and PINless Debit volume and transactions SAN ANTONIO, Nov.

Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

(NASDAQ:LYRA), – Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission – WATERTOWN, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) — Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the

Pure Cycle Announces Financial Results For the Year Ended August 31, 2025

(NasdaqGM:PCYO), DENVER, Nov. 12, 2025 (GLOBE NEWSWIRE) — Pure Cycle Corporation (NASDAQ Capital Market: PCYO) announced its financial results for the year ended August 31, 2025. Pure Cycle reported $13.1 million of net income for the year ended August 31, 2025, which is a 13% increase in net income from 2024 and marks our eighth

Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

(NASDAQ:CELC), Presented detailed efficacy and safety results from the PIK3CA wild-type (“WT”) cohort of the Phase 3 VIKTORIA-1 clinical trial at a late breaking oral presentation at the 2025 European Society for Medical Oncology (“ESMO”) Congress Presented updated clinical results from the Phase 1b portion of a clinical trial evaluating gedatolisib in combination with Nubeqa(R)

Alliance Entertainment Reports First Quarter Fiscal Year 2026 Results

(NASDAQ:AENT), Revenue up 11% to $254M, driven by strength in physical media and collectibles Adjusted EBITDA up 259% to $12.2M; Gross Margin expands 340 basis points to 14.6% Net Income increased to $4.9M, or $0.10 per share, compared to $0.4M in Q1 FY25 AI Implementation delivering early productivity gains across sales and operations Strengthened balance

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

(NASDAQ:IBIO), Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented non-human primate data for our potentially first-in-class Activin E antibody, IBIO-610, which may enable only twice-yearly dosing for the treatment of obesity SAN DIEGO,

Cellebrite Announces Third-Quarter 2025 Results

(NASDAQ:CLBT),(NASDAQ:CLBTW), ARR grew 19% to $439.8 million; Revenue grew 18% to $126.0 million Net income of $20.2 million supports non-GAAP net income of $36.9 million and adjusted EBITDA of $37.7 million, 29.9% adjusted EBITDA margin TYSONS CORNER, Va. and PETAH TIKVA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in

MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress

MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress GlobeNewswire November 12, 2025 Achieved additional $75 million in partnering proceeds from Sanofi and Gilead Granted license to additional preclinical program to Gilead that leverages MacroGenics' novel T-cell engager platform Realigned pipeline priorities by ending development of lorigerlimab in prostate cancer while

Scroll to Top